Recent

% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

  • busy26795 busy26795 Sep 27, 2013 7:47 AM Flag

    DNDN " setting suggest long-lived immunological memory to PROVENGE years following initial treatment."

    DNDN

    Dendreon announces presentation of PROVENGE (sipuleucel-T) data at the 2013 European Cancer Congress; Phase II study demonstrates robust immune response when PROVENGE is administered with abiraterone acetate

    Co announced the presentation of data from clinical studies featuring PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for metastatic castrate-resistant prostate cancer (mCRPC), at the 2013 European Cancer Congress in Amsterdam, September 27-October 1, 2013. Preliminary Phase II data surrounding DN24-02, an investigational autologous cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer, will also be presented. Preliminary data from a Phase II combination study demonstrated that PROVENGE product potency and immunological prime-boost responses are maintained when administered concurrently or sequentially with abiraterone acetate (AA) plus prednisone. Additionally, preliminary data from an ongoing open-label study of PROVENGE treatment in men with mCRPC who were previously treated with PROVENGE in the androgen dependent prostate cancer (ADPC) setting suggest long-lived immunological memory to PROVENGE years following initial treatment.

    Sentiment: Strong Buy